prnewswire.com
Negativewww.prnewswire.com ·
bio techne releases third quarter fiscal 2026 results 302763516
TAX_FNCACT_CHIEF_EXECUTIVE_OFFICERECON_DEBTWB_1104_MACROECONOMIC_VULNERABILITY_AND_DEBTWB_450_DEBT
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedBio-Techne's earnings report shows a slight revenue decline but improved profitability. The company's life science tools and diagnostics segments face mixed demand: large pharma customers are growing, while academic markets are stabilizing. No major supply chain disruption or price shock is indicated. The impact is company-specific with limited broader sector implications.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Bio-Techne Q3 FY2026 revenue declined 2% to $311.4M
- GAAP EPS increased to $0.32 from $0.14 YoY
- Protein Sciences segment sales down 1% to $226.2M
- Diagnostics and Spatial Biology segment sales down 4% to $85.6M
- Large pharma had sixth consecutive quarter of double-digit growth